Cost-effectiveness analysis of fluvastatin and simvatatin for treatment of primary hypercholesterolemia

Objective To evaluate the cost-effectiveness of fluvastatin and simvastatin for treatment of primary hyperholesteromia.Methods A total of 121 patients with primary hyperholesteromia were randomly divided into group A and group B.Patients in group A were treated with 40 mg fluvastatin once each day for 6 weeks,and patients in group B were treated with 20 mg simvastatin once each day for 6 weeks.The side effects of fluvastatin and simvastatin were observed,and their cost-effectiveness were analyzed.Results For group A and group B,the cost of each patient was 1250.96 and 1357.22 Yuan per month,the total positive rate was 91.80% and 90.00% (P0.05),and the incidence of adverse reactions were 5.8% and 5.4% (P0.05) respectively.Conclusion Both fluvastatin and simvatatin can reduce the content of TC,TG,and LDL-C in patients with primary hypercholesterolemia.The two medicines have similar therapeutic effects and good safety,with little side effects.From the perspective of cost-effectiveness,fluvastatin is superior to simvatatin for treatment of primary hyperholesteromia.